NurExone Biologic Inc.
FRC CoverageNurExone Biologic Inc.
FRC CoverageYour view on NRX.V
Overview
What the company does, where it operates, and who runs it.
About NurExone Biologic Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Dr. Lior Shaltiel
- Headquarters
- 1 First Canadian Place Suite 1600 100 King Street West, Toronto, ON, CA
NurExone Biologic Inc., operates as a pharmaceutical technology company.
It is developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of paralysis following spinal cord injury using membrane-bound extracellular vesicles technology, as well as to treat brain trauma injury, and other brain and neurological indications. The company was founded in 2020 and is based in Toronto, Canada.
FRC is paid by the company for coverage
Research Reports
FRC analyst coverage and recommendations.
Research Reports
FRC is paid by the company for coverage
Analyst Notes
Ongoing commentary and updates from FRC analysts.
Jul 21, 2025 · 1y ago · Latest
Company announcement
Preclinical study indicates significant improvement in walking quality in spinal cord injury model
Read the announcementApr 28, 2025 · 1y ago
Company announcement
Expands pipeline with promising preclinical results for facial nerve regeneratio
Read the announcementApr 14, 2025 · 1y ago
Company announcement
Announces U.S. uplisting intention, and closes $2.3M private placement
Read the announcementFRC is paid by the company for coverage
Stock Data
Price chart, volume, and trading data.
FRC Analyst Fair Value
FRC's analysts' fair value estimate and rating, from their research on the company.
About this section
FRC's fair value estimate for NurExone Biologic Inc., and the rating behind it. Set by FRC's analysts in their research on the company: the current estimate, the rating, and when it was last revised. Included with a free account.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for NurExone Biologic Inc.. Starting points for NurExone Biologic Inc.: EPS -C$0.07 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for NurExone Biologic Inc.. NurExone Biologic Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for NurExone Biologic Inc.. Trailing twelve-month EPS for NurExone Biologic Inc. stands at -C$0.07. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for NurExone Biologic Inc.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| ALPSAlps Group Inc | Healthcare | NASDAQ | $36.4M | ||
| ALTAltimmune, Inc. | Healthcare | NASDAQ | $258.8M | ||
| ALXOALX Oncology Holdings Inc. | Healthcare | NASDAQ | $137.0M | ||
| ALZNAlzamend Neuro, Inc. | Healthcare | NASDAQ | $3.7M | ||
| AMBSAmarantus BioScience Holdings, Inc. | Healthcare | OTC | $3,684 | ||
| AMGXFAnGes, Inc. | Healthcare | OTC | $139.1M | ||
| AMLXAmylyx Pharmaceuticals, Inc. | Healthcare | NASDAQ | $3.3B | ||
| AMPEAmpio Pharmaceuticals, Inc. | Healthcare | OTC | $307,285 | ||
| ANABAnaptysBio, Inc. | Healthcare | NASDAQ | $1.4B | ||
| ANEBAnebulo Pharmaceuticals, Inc. | Healthcare | OTC | $95.7M | ||
| ANIXAnixa Biosciences, Inc. | Healthcare | NASDAQ | $84.8M | ||
| ANLAdlai Nortye Ltd. American Depositary Shares | Healthcare | NASDAQ | $453.8M | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for NurExone Biologic Inc.. Coverage tracks NurExone Biologic Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.


Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of NurExone Biologic Inc.